Table 5. Prognostic factors for patients with stages I–III disease according to recurrence-free survival.

	Univariate analyses
	Recurrence-free survival(patients with stages I–III disease and complete resection, n=36)
	Evts/pts	HR	95% CI	P-valuea
Sex
Male vs female	17/34	1.38	0.51–3.74	0.53
Age in years
>65 vs ⩽65	17/34	0.77	0.29–2.0	0.59
WHO PS
2 vs 0–1	12/14	1.20	0.25–5.82	0.82
Disease stage
Stage III vs stages I and II	17/34	0.73	0.28–1.90	0.51
Tumour differentiation
Poorly vs well and moderately differentiated	17/34	1.37	0.39–4.81	0.63
Primary site
Jejunum vs duodenum	17/34	1.09	0.35–3.34	0.89
Ileum vs duodenum	17/34	1.20	0.36–4.01	0.76
Baseline CA19-9 (IU ml−1)
>37 vs ⩽37	10/11	1.11	0.13–9.29	0.93
Baseline CEA (ng ml−1)
>5 vs ⩽5	12/14	2.71	0.30–24.4	0.37
Number of invaded lymph nodes for stage IIIb	17/34	1.05	0.90–1.23	0.54
Number of analysed lymph nodes for stage IIIb	16/32	0.98	0.91–1.04	0.47
Ratio of invaded/analysed lymph nodes for stage IIIb	16/32	3.60	0.61–21.4	0.16
Adjuvant chemotherapy
No vs yes	17/34	0.89	0.31–2.53	0.83
FOLFOX vs 5U	12/22	0.41	0.12–1.38	0.15
P53
Overexpression vs normal	17/34	1.04	0.40–2.70	0.94
β-Catenin
Abnormal vs normal	16/33	0.92	0.30–2.87	0.89
MMR phenotype
dMMR vs pMMR	17/33	0.41	0.13–1.28	0.12
KRAS status
Mutated vs wild	11/26	0.83	0.24–2.84	0.76

Abbreviations: CI=confidence interval; dMMR=mismatch repair deficiency; Evts=events; HR=hazard ratio; pMMR=proficient mismatch repair; PS=performance status; pts=patients; WHO=World Health Organisation.

^aLog-rank test.

^bContinuous variable.